Allogene Therapeutics Inc.

(NASDAQ:ALLO) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact Information

Website: www.allogene.com
Email: Christine.Cassiano@allogene.com
Main Phone: +1 650 457-2700
Address: 210 East Grand Avenue
State: CA
City / Town: South San Francisco
Country: US
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: David D. Chang
Employees: 265
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A